Check out our News below.

Access Accelerated Launches New Resource to Share Learnings in Non-Communicable Disease (NCD) Program Design

Access Accelerated in Action shares experiences from 19 member company NCD access programs implemented in collaboration with more than 50 cross-sector partners

GENEVA, SWITZERLAND – 20 May 2019 – Today, at a side event on the margins of the 72nd World Health Assembly, Access Accelerated, a global partnership of more than 20 biopharmaceutical companies, launched Access Accelerated in Action: Key Learnings in Program Design & Implementation. This resource is the first collective effort from Access Accelerated member companies to share insights from their NCD programs in low- and middle-income countries (LMICs). Access Accelerated in Action is an effort to enhance the impact of public-private partnerships to address the global NCD burden and strengthen health systems in support of Universal Health Coverage (UHC).

According to the World Health Organization, each year, 15 million people under the age of 70 die from NCDs and people in LMICs are disproportionally affected. The vast majority of these premature deaths more than 85 percent occur in LMICs.

Access Accelerated was created to address this growing burden by fostering collaboration between the biopharmaceutical industry and a broad range of stakeholdersincluding people living with NCDs (PLWNCDs), healthcare providers, governments, academia, civil society, multilaterals and others in the private sectorto address barriers to NCD prevention, treatment and care.

Access Accelerated in Action articulates six cross-cutting principles that underpin the initiative’s commitment to strengthening NCD programs: a patient-centered approach; strong local ownership and engagement; substantive partnerships; sustainable, equitable solutions; innovation and continuous learning; and rigorous measurement and transparency. Through a series of 19 case studies, the report examines how member companies have incorporated these principles into their programmatic work.

This resource is intended to spark further collaboration with partners and the broader global health community to broaden and deepen collective knowledge. Through 2019 and beyond, Access Accelerated will be inviting input from the global health community – partners, governments, PLWNCDs, civil society, NGOs and academia – to inform subsequent editions of Access Accelerated in Action. Ultimately, this is in service of supporting all stakeholders’ efforts to address the global NCD burden and improve both the lives of PLWNCDs and their communities.

 “We recognize the biopharmaceutical industry’s role in fostering proactive, collaborative global efforts to strengthen health systems around the world,” said Yoshimi Ohno of Astellas Pharma Inc., who co-led the report’s development. “This report is intended to contribute to building and sharing the knowledge base and experiences of Access Accelerated member companies working on NCD solutions.”

“Access Accelerated members and partners have a unique opportunity to come together and work collaboratively to improve health and advance NCD care in LMICs,” said Rina Sakai of Takeda Pharmaceutical Company Ltd., who also helped lead the report’s development. “By learning from the challenges and successes of the past, as well as understanding opportunities for the future, Access Accelerated in Action is a key resource to support future action.”

Access Accelerated in Action demonstrates the sector’s commitment to sharing information and key learnings, but also serves as a call to action to increase effective multi-sectoral collaboration.

Access Accelerated in Action is another step forward in our commitment to greater transparency and accountability,” said Access Accelerated Director James Pfitzer. “It serves as a call to action to catalyze new, and scale up existing solutions, to tackle the growing NCD burden. We hope this will be a useful resource to continually improve programming and galvanize more collaboration.”

Access Accelerated in Action can be downloaded here:

About Access Accelerated

Access Accelerated is a first-of-its-kind collaboration of more than 20 global biopharmaceutical companies working to reduce barriers to prevention, treatment and care for non-communicable diseases (NCDs) in low-and middle-income countries (LMICs). Launched in 2017, the initiative unites the biopharmaceutical industry to forge partnerships with country governments, civil society, multilateral and non-governmental organizations (NGOs) to address the growing NCD burden. We believe that to address the scale and complexity of the NCD challenge, all sectors must collaborate to strengthen health systems. The initiative is part of the industry’s commitment to help achieve the United Nations Sustainable Development Goals, specifically target 3.4 – by 2030, reduce by one-third pre-mature mortality from NCDs – and support for global momentum around Universal Health Coverage.

For more information about Access Accelerated visit:



Stacy Montejo
+1 202 585 2025

Justine Volet
+41 22 879 85 14


IFPMA (“we”, “us”) owns and operates (“the/our website”). Any person accessing and/or using the website (“the visitor/user”) agrees to the “Terms of Use”, containing the conditions, rules and other provisions with respect to the access and/or use of our website. If you have questions about the “Terms of Use”, please feel free to contact us at


General Use

The material contained on this website is for information only. The website is entitled to be served as an information resource for the internal and external stakeholders of IFPMA, including the general public. Third-Party Websites Links to other websites are provided solely as a convenience and therefore imply neither IFPMA’s responsibility for, nor its approval of the information contained in these websites. Intellectual Property Any use of information from the website should have an acknowledgement of IFPMA/Third-Party as a source respectively, citing the corresponding uniform resource locator (URL). Logo and Name The use of IFPMA’s name and/or logo is prohibited without prior express authorization from IFPMA. The access and/or use of the website does not permit to copy, reproduce, modify, distribute or elsehow exploit IFPMA’s name and/or logo except with the prior explicit permission. Abuse and Violation Any abuse or violations of the Terms of Use and/or Privacy Policy should be reported to


IFPMA renounces any liability or responsibility for any damages of any nature whatsoever resulting from the use of, inability to use, and/or reliance on the material and information contained on our website. IFPMA makes no representations or warranties as to the completeness or accuracy of any of the information available on the website as well as does not provide any warranties regarding the security of the content of our website or any linked websites. IFPMA endeavours to make its best effort to keep the information accurate and updated on a regular basis, however this is not claimed to be exhaustive. IFPMA does not guarantee that the website is continuously available and error-free at all times.

Privacy Policy

IFPMA is committed to protecting the privacy and security of visitors to our website. Outlined below is our online privacy policy for information collected through our website. If you have questions about these policies, please feel free to contact us at

Personal Information

We constantly analyse our website logs to improve the value of our website. We do not use this analysis to record or track any personally identifiable information of our visitors. If you are asked to provide personal information such as your name, e-mail or/and postal address when requesting information, providing feedback, registering to a newsletter, or using any other functions of the website, be assured that all such information is considered by IFPMA both private and secure. IFPMA does not share or sell your personal information to third parties. Under no circumstance will details be disclosed publicly, except in order to comply with any legal obligation. This policy reiterates that IFPMA fully appreciates the importance of online privacy and is committed to protecting your personal information.

Use of Cookies Files

Our website is enhanced by cookie files to personalize and customize the experience of our visitors and to support some necessary functions. IFPMA collects broad usage statistics using Google Analytics, to better understand how our visitors use our website, and to help us improve visitors’ experience. Such information includes the IP address (where available), browser type, and any additional information provided by a browser during the use of our website. The statistical data about our users’ browsing actions and patterns does not identify any individual. You may choose to accept or refuse cookies by modifying your browser preferences. If you wish to get notified when a cookies are set, this option should also be available in your browser settings. Please note that if you reject some or all cookies, your experience at this and other websites throughout the Internet may not be complete.

Payment Transactions

To enable IFPMA to process any order or registration to an event, a secure online payment system may be used to process payments using credit card details. IFPMA will not be collecting or storing credit card details in our system.

Third-Party Websites

Please be aware that other websites to which links may be provided, including social media, may collect visitor’s personally identifiable information when accessed. The information collection practices of other websites linked to IFPMA’s website are not covered by this Privacy Policy.

This website uses cookies to ensure you get the best experience on our website. Learn More